Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Mobocertinib→

Mobocertinib Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1847461-43-1
Molecular formula
C32H39N7O4
Molecular weight
585.71 g/mol
Drug class
Irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitorhistorical antineoplastic small molecule
Mechanism of action
Irreversibly inhibits EGFR kinase, including mutant EGFR exon 20 insertion variants, reducing downstream oncogenic signalling. The drug had an accelerated US approval for EGFR exon 20 insertion-mutated NSCLC, but that indication was withdrawn in July 2024 after confirmatory evidence did not verify clinical benefit.
Indications / reported uses
  • Historical US indication: treatment of adults with locally advanced or metastatic EGFR exon 20 insertion-mutated non-small-cell lung cancer (NSCLC) whose disease had progressed on or after platinum-based chemotherapy. The US approval was withdrawn 15 July 2024; do not present this as a current US-authorised treatment.

Sources: US FDA — Withdrawn cancer accelerated approvals · Federal Register — Withdrawal of EXKIVITY approval, 15 July 2024 · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Mobocertinib Environmental Risk Assessment (ERA) (the Mobocertinib ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.